Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy.

Abstract

Heavily-treatment-experienced people living with human immunodeficiency virus (HTE-PLWH) represent a population with limited therapeutic options and at high-risk of clinical progression, morbidity, and mortality. The development of new drugs and new drug classes for the treatment of HIV-1 infection in HTE-PLWH is critical to successfully suppress HIV-1 replication, restore the immune system, and improve quality of life. Fostemsavir is the first attachment inhibitor approved by Food and Drug Administration and European Medicines Agency for the treatment of HIV-1 infection. It is approved in combination with other antiretrovirals, for HTE-PLWH with multi-drug resistant HIV-1 after failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. In this review, we present and discuss the mechanism of action, the pharmacodynamic and pharmacokinetic properties, and the efficacy and safety of fostemsavir as an antiretroviral agent for the treatment of HIV-1 infection.

• Authors: Camilla Muccini, Diana Canetti, Antonella Castagna, Vincenzo Spagnuolo
• Journal: Drug design, development and therapy (Drug Des Devel Ther) Vol. 16 Pg. 297-304 ( 2022) ISSN: 1177-8881 [Electronic] New Zealand
• PMID: 35115764 (Publication Type: Journal Article, Review)
• Copyright: © 2022 Muccini et al.

Chemical References

• Anti-HIV Agents
• Organophosphates
• Piperazines
• fostemsavir

Topics

• Anti-HIV Agents (therapeutic use)
• HIV Infections (drug therapy)
• HIV-1 (drug effects)
• Humans
• Organophosphates (therapeutic use)
• Piperazines (therapeutic use)